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Abstract
Background: ApoJ/clusterin is a multifunctional protein highly expressed in the brain. The implication of ApoJ in β-
amyloid (Aβ) fibrillization and clearance in the context of Alzheimer’s disease has been widely studied, although the
source and concentration of ApoJ that promotes or inhibits Aβ cerebral accumulation is not clear yet. ApoJ is abundant
in plasma and approximately 20% can appear bound to HDL-particles. In this regard, the impact of plasmatic ApoJ and its
lipidation status on cerebral β-amyloidosis is still not known. Hence, our main objective was to study the effect of a
peripheral increase of free ApoJ or reconstituted HDL particles containing ApoJ in an experimental model of cerebral β-
amyloidosis.
Methods: Fourteen-month-old APP23 transgenic mice were subjected to subchronic intravenous treatment with rHDL-
rApoJ nanodiscs or free rApoJ for 1month. Aβ concentration and distribution in the brain, as well as Aβ levels in plasma
and CSF, were determined after treatments. Other features associated to AD pathology, such as neuronal loss and
neuroinflammation, were also evaluated.
Results: Both ApoJ-based treatments prevented the Aβ accumulation in cerebral arteries and induced a decrease in total
brain insoluble Aβ42 levels. The peripheral treatment with rApoJ also induced an increase in the Aβ40 levels in CSF,
whereas the concentration remained unaltered in plasma. At all the endpoints studied, the lipidation of rApoJ did not
enhance the protective properties of free rApoJ. The effects obtained after subchronic treatment with free rApoJ were
accompanied by a reduction in hippocampal neuronal loss and an enhancement of the expression of a phagocytic
marker in microglial cells surrounding Aβ deposits. Finally, despite the activation of this phagocytic phenotype, treatments
did not induce a global neuroinflammatory status. In fact, free rApoJ treatment was able to reduce the levels of
interleukin-17 (IL17) and keratinocyte chemoattractant (KC) chemokine in the brain.
Conclusions: Our results demonstrate that an increase in circulating human rApoJ induces a reduction of insoluble Aβ
and CAA load in the brain of APP23 mice. Thus, our study suggests that peripheral interventions, based on treatments
with multifunctional physiological chaperones, offer therapeutic opportunities to regulate the cerebral Aβ load.
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Background
Cerebral β-amyloidosis is characterized by the accumula-
tion of β-amyloid (Aβ) protein in the brain parenchyma
and in cerebral vessels, which are major features of Alzhei-
mer’s disease (AD) and cerebral amyloid angiopathy
(CAA), respectively [1, 2]. Both diseases are characterized
by devastating clinical presentations together with a high
prevalence in the elderly population. In this sense, AD is
the first cause of dementia affecting 24 million people
worldwide [3, 4]. AD patients show severe β-amyloidosis
characterized by the presence of parenchymal Aβ deposits,
together with intracellular accumulation of hyperpho-
sphorylated TAU protein (neurofibrillary tangles) triggering
neuroinflammation, neurodegeneration, and dementia [2].
CAA, on the other hand, is characterized by Aβ deposition
in brain vessels causing dementia and being the leading
cause of lobar intracerebral hemorrhage (ICH) in the eld-
erly population [5]. The Aβ peptide is the product of the
amyloid precursor protein (APP) processed by β- and
γ-secretases, giving rise to peptides of different lengths, in-
cluding Aβ40 and Aβ42, which are the most interesting
forms from a clinical point of view. Although both Aβ pep-
tides are prone to aggregate-forming amyloid fibrils that de-
posit in the brain, Aβ42 preferentially deposits in the
parenchyma (forming neuritic plaques), whereas Aβ40 is
more commonly associated with CAA-affected vessels [6,
7].
The underlying mechanisms explaining pathological
Aβ accumulation in the brain are not completely clear.
Defective routes of Aβ elimination have been proposed
as an important factor leading to sporadic cerebral
β-amyloidosis [8]. In this context, the most relevant Aβ
clearance pathways described to date include proteolytic
degradation by extracellular proteases, such as
insulin-degrading enzyme (IDE) and neprilysin (NEP)
[9]; clearance across the blood-brain barrier (BBB) by
binding to specific receptors, such as LRP-1 and LRP-2,
among others [10]; and through perivascular drainage
[11], promoting the mobilization of Aβ material along
the basement membrane of cerebral arteries and capil-
laries to the cervical lymph nodes for its elimination. Fi-
nally, Aβ can be eliminated through glial uptake by
astrocytes, microglia, and myeloid cells derived from
peripheral monocytes followed by intracellular digestion
[12–14]. Microglial cells are resident innate immune
cells that play an important role in mediating the neu-
roinflammatory process in the brain and the phagocyt-
osis of toxic species such as Aβ material. In this context,
the importance of this dual role of microglia in cerebral
β-amyloidosis is increasingly recognized [15]. At this
juncture, therapeutic strategies stimulating these elimin-
ation pathways have been proposed for AD.
Certain apolipoproteins, beyond their role in lipid and
cholesterol metabolism, have been shown to modulate
Aβ accumulation in the brain. APOE genotype is the
strongest genetic risk factor for the development of
sporadic cerebral β-amyloidosis [16, 17], and although
its interaction with Aβ is not well understood, it has
been proposed that apolipoprotein E (ApoE) influences
Aβ fibrillization [18], together with its clearance across
the BBB [19]. On the other hand, apolipoprotein J (ApoJ,
also known as clusterin) is one of the most highly
expressed apolipoproteins in the brain after ApoE [20].
A crucial role of ApoJ in cerebral β-amyloidosis is sup-
ported by several lines of evidence, although its precise
role is not well determined. ApoJ is a heterodimeric
multifunctional protein. It has been described as an
anti-inflammatory and antiapoptotic protein [21, 22] and
a regulator of complement activation [23]. In addition, it
is a very effective chaperone that is able to bind to par-
tially misfolded proteins. In this context, ApoJ is able to
bind to Aβ and prevent its fibrillization [24] and toxicity
in vitro [25]. In AD brains, ApoJ is codeposited with
neuritic plaques and CAA-affected vessels, and ApoJ-Aβ
complexes have been detected in cerebrospinal fluid
(CSF) [26]. The role of ApoJ in AD was further sup-
ported by a GWAS (genome-wide association study) that
identified the CLU locus as a risk factor for developing
this neurological disease [27]. More revealingly, the risk
factor allele rs11136000C was associated with low ex-
pression of ApoJ, whereas the protective allele
rs11136000T caused higher ApoJ expression [28]. On the
other hand, elevated circulating levels of ApoJ in plasma
have been related to the severity and prevalence of AD
[29]. This last piece of evidence suggests that an increase
in ApoJ levels would occur as a protective response
against the aberrant accumulation of Aβ in the brain.
However, there are conflicting results in the literature
regarding the protective role of ApoJ. This is the case in
a study showing that PDAPP mice lacking Clu (PDPP/
Clu) presented reduced fibrillary Aβ without altering
total levels of Aβ [30]. On the other hand, Wojtas and
colleagues observed that knocking out Clu in APP/PS1
mice resulted in an exacerbation of vascular Aβ depos-
ition, whereas total Aβ and parenchymal Aβ deposition
were remarkably reduced [31]. In this sense, more re-
cently, it has been described that the Clu deficiency in
the 5xFAD mouse AD model reduces the different Aβ
pools only in young mice, although this effect disappears
with age [32]. Nevertheless, the impact of increasing
ApoJ in the circulation and/or in the brain still needs to
be clarified.
From this background, our main objective was to
understand the role of ApoJ in the development and
progression of cerebral β-amyloidosis by determining
the potential effect of ApoJ-based therapies in an experi-
mental model of AD. Because ApoJ is present in plasma
as free/nonlipidated form or associated with HDL
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(high-density lipoproteins) particles (20% of circulating
ApoJ) [33], we also analyzed whether lipidation of ApoJ
could induce functional modifications associated with
Aβ distribution in the brain. For this purpose, we ana-
lyzed the effect of peripheral administration of human
recombinant ApoJ (h-rApoJ) in nonlipidated (free rApoJ)
and lipidated (reconstituted HDL nanodiscs formulated
with rApoJ, rHDL-rApoJ nanodiscs) [34] structural
states, in terms of cerebral Aβ accumulation, neuronal
loss, and neuroinflammation in aged APP23 transgenic
mice.
Methods
Human recombinant ApoJ
The production of functional human recombinant ApoJ
(rApoJ) has been previously reported by our group [34,
35]. Briefly, human embryonic kidney 293 T cells
(HEK293T) were transfected with the pcDNA4.0™ vector
containing the human APOJ cDNA (Abgent, Clairemont,
San Diego, USA). Stable transfected cells were grown in
HYPERFlask systems (Corning Inc., New York, USA)
followed by the recollection of cell supernatants for pro-
tein purification with Ni-affinity chromatography with fast
protein liquid chromatography (FLPC; AKTA Purifier 100
system, GE Healthcare Bio-Sciences Corp., Piscataway, NJ,
USA) in HiScreen Ni FF columns (GE Healthcare). The
purified protein was dialyzed overnight (ON) at 4 °C
against tris buffer saline (TBS) in 10 KDa SnakeSkin Dialy-
sis Tubing membranes (Thermo Fisher, Waltham, MA,
USA). We confirmed that the produced human rApoJ was
a mature-secreted protein formed as a heterodimeric
complex of two 40–45 kDa subunits [34]. For those
batches intended to the preparation of reconstituted HDL
particles, the resulting purified rApoJ was dialyzed against
TBS (pH = 6.4). Finally, the protein concentration was de-
termined by BCA assay (Thermo Fisher) and diluted to a
final rApoJ concentration of 200 μg/ml in PBS. Aliquots
were stored at − 80 °C until its usage.
Preparation and purification of rHDL-rApoJ nanodiscs
A detailed protocol for the preparation and purification
of reconstituted HDL nanodiscs formulated with rApoJ
(rHDL-rApoJ nanodiscs) has been previously published
by our group [34]. Briefly, the process started with lipid
mixture preparation with 1,2-dimyristoyl-sn-glycero-3--
phosphocholine (DMPC, Avanti Polar Lipids, Alabaster,
AL, USA) and free cholesterol (CHOL, Sigma-Aldrich,
Saint Louis, MO, USA) in chloroform solution (5:1
DMPC:CHOL molar ratio). The organic solvent was re-
moved under vacuum and nitrogen to afford a dry lipid
film, followed by rehydration with TBS 40 mM sodium
deoxycholate (cholate, Sigma-Aldrich). This suspension
was incubated 30min at 37 °C until achieving a clear so-
lution containing the DMPC/CHOL/cholate mixed
micelles. For the preparation of rHDL-rApoJ nanodiscs,
mixed micelles were incubated with free rApoJ at
550:110:1 DMPC/CHOL/rApoJ molar ratio and three in-
cubation cycles were performed at 4 °C and 37 °C to pro-
mote the lipid-protein interaction. After incubation, the
rHDL-rApoJ nanodiscs self-assembly started with the
cholate removal through extensive dialysis against
1000-fold excess TBS at 4 °C during 48 h in 10 KDa
SnakeSkin Dialysis Tubing with two buffer changes (1 ×
109 overall dilution factor). Finally, dialyzed samples
were centrifuged at 16000×g for 30 min at 4 °C to elim-
inate the unbound lipids. A purification step with potas-
sium bromide (KBr; Sigma Aldrich) density gradient
ultracentrifugation was needed to allow the elimination
of unbound free rApoJ. This step (100,000×g; 24 h, 1250
mg/ml density of KBr), allowed the recollection of puri-
fied rHDL-rApoJ in the upper fractions (< 1250mg/ml
density). These samples were dialyzed against PBS-2%
sucrose to eliminate KBr. The protein concentration was
determined by BCA (Thermo Scientific). rHDL-rApoJ
containing solutions were diluted in PBS to a final rApoJ
concentration of 200 μg/ml, and aliquots were stored at
− 80 °C until its usage.
Subchronic in vivo administration of rHDL-rApoJ
nanodiscs and free rApoJ
Mice were housed in a climate-controlled environment on
a 12/12-h light/dark cycle with food and water available ad
libitum. The effect of the subchronic administration of both
rHDL-rApoJ nanodiscs and free rApoJ was studied in male
APP23 transgenic mice (Hemizygote B6,
D2-TgN[Thy-APPSWE]-23-Tg mice, Novartis, Basel,
Switzerland) [36]. Male APP23 mice were used in order to
diminish variation in age-related Aβ deposit quantification,
since male and female APP23 mice differ in the age at
which Aβ deposition begins. These transgenic mice overex-
press the APP protein with the Swedish mutation (K670M/
N671L) under the murine neuronal Thy1 promoter (thymo-
cyte antigen-1). Hemizygous APP23 mice were backcrossed
with C57BL/6 mice (Janvier Labs, Le Genest-Saint-Isle,
France), and the APP genotype was tested in the offspring
by Transnetyx (Cordova, TN, USA). Wild-type (wt) and
APP23 mice were aged in the animal facility of our institu-
tion to obtain the final study cohort. APP23 mice received 8
intravenous (IV) doses of rHDL-rApoJ or free rApoJ (1mg/
kg of rApoJ) or saline for 4 weeks (2 doses/week). The age
(mean ± SD) at the beginning of the treatment for each
APP23 group was 14.00 ± 0.73months old for the
saline-treated mice (N = 7), 14.07 ± 0.75months old for the
rHDL-rApoJ-treated mice (N= 7) and 13.99 ± 0.47months
old for the free rApoJ-treated mice (N = 7). For the adminis-
tration of treatments, mice were anesthetized with isoflur-
ane (5% for induction and 2% for maintenance in medicinal
air/oxygen, Abbot Laboratories, Spain) followed by
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retro-orbital sinus injection, selected as a reliable adminis-
tration route for IV delivery [37]. All animals completed the
treatment, which was not associated with mortality or body
weight loss. All assays conducted in mouse brains after
treatment were evaluated in a blinded manner.
Cerebrospinal fluid collection
Thirty minutes after the last administration, mice were
anesthetized under isoflurane and CSF was sampled as
previously described [38]. Briefly, anesthetized mice were
placed in the stereotaxic instrument and a sagittal section
inferior of the occiput was done in the skin. Once the dura
mater of the cistern magna was visualized under the
microscope, it was penetrated with a glass capillary (inner
diameter of 0.5 mm) and clear CSF ascended by capillarity.
Only completely clear CSF was considered for further
experiments.
Blood and brain collection
Blood was collected through cardiac puncture, and
blood samples were centrifuged in ethylenediaminetetra-
cetic acid (EDTA) tubes to recollect the EDTA-plasma.
Then, after transcardial perfusion with 25ml of cold PBS
(pH = 7.4), brains were rapidly removed and divided into
two hemispheres. One of the hemispheres was frozen at
− 80 °C for homogenization, while the other was fixed in
10% formalin (Diapath, Martinengo, Italy) at room
temperature (RT) for 48 h before paraffin embedding.
Brain homogenates
One of the hemispheres of each mouse was homogenized to
obtain soluble, membrane-associated, and insoluble fractions
through sequential centrifugations. First, the brain tissue
was homogenized in 4ml of TBS (pH= 7.4) supplemented
with cOmplete EDTA-free protease inhibitor cocktail
(Roche Diagnostic, Mannheim, Germany) and samples were
centrifuged at 8000×g for 30min a 4 °C. The supernatant
was selected as the soluble fraction whereas the pellet was
homogenized in TBS supplemented with TritonX-100 and
protease inhibitors followed by centrifugation at 8000×g for
30min at 4 °C. The supernatant was selected as the
membrane-bound fraction whereas the pellet was homoge-
nized in 5M guanidine-HCl (pH= 8, Sigma-Aldrich) sup-
plemented with protease inhibitors. Samples were shaken
for 3 h at RT followed by centrifugation at 8000×g for 30
min at 4 °C, and the supernatant was selected as the insol-
uble fraction. Soluble, membrane-bound, and insoluble frac-
tions were aliquoted and frozen at − 80 °C. The protein
concentration of each fraction was quantified by BCA assay
(Thermo Fisher).
Enzyme-linked immunosorbent assay (ELISA)
Aβ levels in plasma, CSF, and soluble and insoluble brain
fractions were quantified with commercial ELISA kits
for both Aβ40 (KHB3481) and Aβ42 (KHB2442, Thermo
Fisher). Levels of human ApoJ in plasma of treated mice
were quantified with the commercial ELISA kit
(3713-1HP, Mabtech, Nacka Strand, Sweden). Levels of
the endogenous mouse ApoJ in brain homogenates and
plasma in APP23 mice were determined using the
mouse Clusterin ELISA Kit (ab199079, Abcam, Cam-
bridge, UK). Commercially available multiplexed ELISA
was used to investigate the general inflammatory state in
brain soluble fraction after treatments (Mouse cytokine
magnetic 20-plex panel, LMC0006M, Invitrogen). Re-
sults were analyzed in duplicate with Luminex technol-
ogy in a MAGPIX™ instrument, and samples with a
coefficient of variation (CV) > 35% were excluded. In all
cases, data were corrected by the amount of total pro-
tein determined by BCA.
Immunohistochemistry
A series of three paraffin-embedded sagittal sections
were selected 800 μm apart, starting from the division
between the hemispheres. For the detection of Aβ with
conventional immunohistochemistry (IHC), all samples
were deparaffinized for 1 h at 65 °C, rehydrated, and
treated with 2% H2O2 and 10% methanol in PBS for 15
min. The samples were incubated for 1 h in blocking so-
lution (PBS, 0.2% Triton-X, 10% fetal bovine serum
(FBS, Millipore, Darmstadt, Germany) followed by ON
incubation with the anti-Aβ monoclonal antibody 4G8
(BioLegend, San Diego, CA, USA) diluted 1:10000 in
blocking solution. Next, slices were incubated with bio-
tinylated anti-mouse IgG (Vector Laboratories, Burlin-
game, CA, USA) diluted 1:200 in blocking solution for 1
h at RT and with streptavidin-HRP (Vector Laboratories)
diluted 1:200 in blocking solution for 1 h at RT. Finally,
diaminobenzidine (DAB; Dako, Denmark) was applied to
the samples until a brown end-product was observed.
Contrast staining was performed by immersion of the
samples in Harris hematoxylin solution (Sigma-Aldrich).
To quantify the number of Aβ-positive deposits, we used
the overview tool of a Leica LMD 6500 Laser Microdis-
section Microscope System to scan each brain slice in
full. Overview images were labeled with codes to ensure
blind quantification. The number of Aβ deposits larger
than 50 px2 in the cortex and the area (px2) occupied
per deposit were quantified with ImageJ software. Three
different deep sections per brain were analyzed, and a
mean of the values determined in those sections was ob-
tained. Data are expressed as the number of Aβ-positive
deposits per total area (px2) and the mean size of those
Aβ-positive deposits. Representative images were ob-
tained with a conventional microscope (BX61, Olympus,
Tokyo, Japan).
An immunohistochemistry protocol was also per-
formed for the quantification of NeuN-positive cells in
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the cortex and hippocampus (CA1, CA2/CA3, and poly-
morphic layer of dentate gyrus (poDG)) of APP23 and
age-matched wt mice in the first deep-section slice. Be-
fore the blocking step, an antigen retrieval step was per-
formed by immersing the slices in citrate buffer (10 mM
sodium citrate, 0.05% TWEEN-20, pH = 6) at 95 °C for
30 min. The NeuN antibody (Millipore) was diluted
1:200 in blocking solution. The quantification of
NeuN-positive cells in the different areas was performed
as previously described [39]. Briefly, for each sample and
brain region, three different images were taken at × 40
magnification using an LMD6500 microscope (Leica,
Wetzlar, Germany). NeuN-positive cells were counted in
three different squares in every image measuring 150 ×
150 μm in cortical regions, whereas squares measuring
100 × 100 μm were used in hippocampal regions. The re-
sults are expressed as the number of NeuN-positive cells
per square millimeter.
Thioflavin S staining
Thioflavin S (ThS) staining was performed to detect fi-
brillar Aβ deposits in brain slices. After deparaffination
and rehydration, a series of 3 selected sagittal sections
800 μm apart were immersed in ThS (Sigma-Aldrich) 1%
solution in 75% ethanol for 30 s. The excess of ThS was
drained, and the sections were immersed in ThS 0.1% in
75% ethanol for 1 min. Finally, the slices were dehy-
drated, and DAPI (4′,6-diamidino-2-phenylindole) was
used for counterstaining before the preparations were
mounted. The number of ThS-positive deposits, the size
of those deposits, and the number of ThS-positive brain
vessels were quantified as previously described for the
quantification of Aβ deposits by immunohistochemistry.
The count of ThS-positive deposits larger than 50 px2
and the analysis of the area (px2) occupied per deposit
were quantified with ImageJ software. Data are
expressed as the number of CAA-affected vessels
(ThS-positive brain vessels), the number of ThS-positive
deposits per total area (px2) and the mean size of
ThS-positive deposits. Representative images were ob-
tained with a conventional fluorescence microscope
(BX61, Olympus, Tokyo, Japan).
Immunofluorescence
A cluster of differentiation 68 (CD68) as a marker of
phagocytosis and Tomato lectin (TL) as vascular and
microglia marker [40] were analyzed through immuno-
fluorescence in paraffin-embedded brain sections. To
this end, after deparaffination, rehydration, and antigen
retrieval with citrate buffer (10 mM sodium citrate,
0.05% Tween20, pH = 6, 30 min at 95 °C), slices were
blocked in PBS pH = 7.4 supplemented with 10% FBS
and 1% Tween 20 for 1 h at RT. Rabbit anti-mouse
CD68 antibody (Abcam) diluted 1:50 in blocking
solution was incubated ON at 4 °C. Next, secondary
antibody anti-rabbit-AlexaFluor488 (Thermo Fisher) di-
luted 1:500 in blocking solution was incubated 1 h at RT
followed by incubation with Tomato lectin-DyLight564
(Vector Laboratories) diluted 1:100 in blocking solution
1 h at RT. On the other hand, the localization of CD68
and Aβ was analyzed in paraffin-embedded brain sec-
tions. After the deparaffination and rehydration steps,
brain slices were treated with 70% formic acid for 10
min followed by 3 washes of 5 min with PBS-1%
Tween20. Then, the samples were incubated in blocking
solution for 1 h at RT followed by ON incubation at 4 °C
with mouse anti-human Aβ monoclonal antibody (4G8) di-
luted 1:1000 and rabbit anti-mouse CD68 (Abcam) diluted
1:50 or rabbit anti-Iba1 (ionized calcium binding adapter
molecule-1, Abcam) diluted 1:100 in blocking solution.
Next, secondary antibodies anti-rabbit-AlexaFluor-488 and
anti-mouse-AlexaFluor694 (Thermo Fisher) diluted 1:500
in blocking solution for 1 h at RT. Finally, contrast staining
was done with DAPI before mounting the preparations. Im-
ages were obtained with a conventional fluorescence micro-
scope (BX61, Olympus). Finally, human ApoJ was analyzed
in brain sections of treated animals. To this end, after the
rehydration, antigen retrieval, and blocking steps, brain
slices were incubated ON with mouse-anti-human ApoJ
(BD Bioscience, San Jose, CA, USA) diluted 1:100 in block-
ing solution. AlexaFluor-594 was used as a secondary anti-
body (1:500), and DAPI was used as contrast staining.
Images were obtained with a confocal spectral microscopy
(FV1000, Olympus).
Western blot
For the immunodetection of different protein profiles,
40 μg of soluble or membrane-bound brain homogenate
fractions or 1 μl of mouse plasma was loaded in 10%
acrylamide SDS-PAGE under reducing conditions (5%
β-mercaptoethanol and sample heating at 95 °C). Then,
gels were transferred onto nitrocellulose membranes
using Trans-Blot Turbo transfer system (Bio-Rad,
Hercules, CA, USA) at 1.3 A, 25 V for 10 min and block-
ing was done in 10% non-fatted milk for 1 h at RT.
Membranes were incubated in tested specific antibodies
diluted in blocking solution at 4 °C ON. Suitable second-
ary HRP-labeled antibodies diluted in blocking solution
were incubated 1 h at RT. The processing of membranes
continued with the incubation with PierceECL Western
blotting Luminol/Enhancer and Stable Peroxidase solu-
tions (Thermo Fisher). The relative amount of the tar-
geted protein was calculated from the quantification of
the mean intensity with the ImageJ software. Immuno-
blotting of β-actin, β-tubulin, or glyceraldehydes
3-phosphate dehydrogenase (GADPH) was used as load-
ing controls. The primary antibodies used were rabbit
anti-CD68 (1:1000, Abcam), rabbit anti-GFAP (Glial
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Fibrillary Acidic Protein, 1:1000, Dako), rabbit anti-Iba1
(1:1000, Abcam), mouse anti-LRP1 (1:1000, Abcam),
mouse anti-human APP (1:1000, Millipore), mouse
anti-sAPPα (Soluble APP fraction-α, 1:1000, Clontech,
Mountain View, CA, USA), mouse anti-sAPPβ (Soluble
APP fraction-β, 1:1000, Clontech), rabbit-anti RAGE
(1:1000, Abcam), goat-anti-mouse ApoJ (1:1000, RD Sys-
tems, Minneapolis, MN, USA), mouse anti-β-actin
(1:10000, Sigma-Aldrich) and mouse anti-GADPH
(1:10000, Invitrogen). The following HRP-labeled sec-
ondary antibodies were used: Anti-rabbit-HRP (1:2000,
GE Healthcare Biosciences, Little Chalfont, UK),
anti-mouse-HRP (1:2000, GE Healthcare Bioscience),
and anti-goat-HRP (1:5000, Sigma-Aldrich).
Microglial cell cultures
The mouse microglial cell line BV-2 was obtained from the
European Collection of Authenticated Cell Culture
(ECACC). BV-2 cells were seeded (30.000 cells/well) in
poly-L-lysine (Sigma-Aldrich)-coated sterile coverslips in
24-well plates and incubated at 37 °C in RPMI 1640 medium
(Thermo Fisher) supplemented with 10% fetal bovine serum
(FBS, Thermo Fisher) and 1% penicillin-streptomycin
(Thermo Fisher) for 24 h. For treatments, the medium was
changed to RPMI containing 0.1% FBS and cells were incu-
bated with or without rApoJ (0.1 μM) for 24 h as a
pre-treatment. Then, rApoJ was removed by washing the
wells with RPMI 0.1% FBS and 0.5 μM human Aβ(1–40)
HiLyteTM Fluor 488-labeled (AnaSpec, Fremont, CA, USA)
was added for 3 h to the corresponding wells. Next, cells
were washed twice with PBS containing 5% bovine serum
albumin (BSA, Sigma-Aldrich) and fixed with 4% parafor-
maldehyde (PFA, Sigma-Aldrich) for 15min. After fixation,
cells were washed twice with PBS and levels of 488-Aβ(1–
40) in the cells were analyzed by measuring the fluorescence
(Ex/Em= 503/528 nm) using a Synergy Mx microplate
reader (Biotek). To visualize the cellular structure, a
phalloidin-tetramethylrhodamine B isothiocyanate (phalloi-
din-TRITC, Sigma-Aldrich) actin staining was used (50 μg/
ml in PBS for 20min). After washing twice with PBS, the
coverslips were mounted on slides using FluoroshieldTM
with DAPI (Sigma-Aldrich). Images were obtained with con-
focal spectral microscopy (FV1000, Olympus).
Statistical analysis
GraphPad Prism 6 and SPSS Statistics 17.0 software
were used for the statistical analysis. The normality of
distributions was assessed with the Shapiro-Wilk nor-
mality test. The differences were assessed using a t test
or one-way ANOVA with an LSD (least significant dif-
ference) post hoc test when appropriate. When data did
not fit a normal distribution, the Kruskal–Wallis test
with a Dunn’s post hoc was used for multiple compari-
sons, and the Mann–Whitney test was used for
one-to-one comparisons. The Benjamini-Hochberg false
discovery rate (FDR) correction was used to control for
multiple testing in the multiplexed analysis of brain in-
flammatory status. A p value < 0.05 was considered sta-
tistically significant.
Results
APP23 mice are characterized by increasing accumula-
tion of both human Aβ40 and Aβ42 in the brain. This ris-
ing Aβ deposition became especially evident in very old
APP23 mice (24 months old), where a 20-fold increase
in insoluble Aβ40 and a 10-fold increase in insoluble
Aβ42 were observed in comparison with the correspond-
ing Aβ load in 15-month-old APP23 mice (Fig. 1a, b).
Interestingly, this growing Aβ accumulation was accom-
panied by an increase in mouse ApoJ (m-ApoJ) levels in
the brain (Fig. 1c). Twenty-four-month-old APP23 mice
presented significantly higher m-ApoJ brain levels than
age-matched wt mice, whereas the difference between
genotypes was nonsignificant in 15-month-old mice. In
addition, as expected, this increase in brain m-ApoJ was
exacerbated with age, as significant differences in
m-ApoJ levels were detected between 15- and
24-month-old APP23 mice. Plasma levels of endogenous
m-ApoJ were also determined, although no significant
differences between genotypes were found in 15- or
24-month-old mice (Fig. 1d).
The endogenous increase in m-ApoJ in APP23 mice at
late pathological stages could be interpreted as a physio-
logical protective mechanism to promote reduction and
clearance of Aβ in the brain. In this regard, we won-
dered whether an earlier increase in ApoJ levels could be
a beneficial strategy to delay the Aβ deposition detected
over time. Therefore, our main objective was to study
the effect of peripheral administration of free rApoJ or
lipidated rApoJ (rHDL-rApoJ nanodiscs) in APP23 mice.
To this end, APP23 mice received 8 intravenous admin-
istrations (over the course of 1 month) of free rApoJ (1
mg/kg), rHDL-rApoJ (1 mg/kg), or saline, with 2 infu-
sions/week (Fig. 2a). The administered dose of 1 mg/kg
of human rApoJ would theoretically lead to a mean in-
crease of 20% in total circulating ApoJ levels considering
the m-ApoJ levels determined in plasma. The equality of
the initial amounts of infused rHDL-rApoJ and free
rApoJ was confirmed by Western blot, as shown in
Fig. 2b, where the α- and β-chains of rApoJ were ob-
served at ≈ 37 KDa. Next, the circulating concentration
of human rApoJ (h-rApoJ) was quantified by ELISA. A
significant increase in plasma levels of h-rApoJ was ob-
served in both rHDL-rApoJ- and free rApoJ-treated
mice, whereas human ApoJ, as expected, was not de-
tected in the saline group (Fig. 2c). In addition, no sig-
nificant differences in h-ApoJ between the rHDL-rApoJ-
and free rApoJ-treated groups were found in plasma 30
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min after administration. On the other hand, the levels
of h-rApoJ in brain homogenates were undetectable by
ELISA (< 70 pg/ml) 30 min after the last administration
of the subchronic treatment (Fig. 2d). However, im-
munofluorescence analysis revealed specific staining for
h-ApoJ in occasional vessels from the brains of both
rHDL-rApoJ- and free rApoJ-treated mice. Brains from
saline-treated mice did not present human ApoJ staining
(Fig. 2e). On the other hand, h-rApoJ-based peripheral
treatments did not influence the expression of m-ApoJ
in brain homogenates or m-ApoJ levels in plasma, as de-
tected by ELISA (Additional file 1: Figure S1).
The efficacy of subchronic rApoJ-based treatments in
APP23 mice was first evaluated in terms of cerebral Aβ
load. Levels of Aβ40 and Aβ42 in soluble and insoluble
fractions of brain homogenates were quantified by
ELISA after the treatments (Fig. 3a–c). The levels of sol-
uble Aβ40 were not significantly different among treat-
ments, although a trend towards a reduction in free
rApoJ-treated mice was observed (p = 0.09). Soluble
Aβ42 levels were under the lower limit of detection (< 6
pg/ml). Interestingly, we observed lower levels of both
insoluble Aβ40 and Aβ42 in mice treated with free rApoJ
than in the saline-treated group (insoluble Aβ40 1.01 ±
0.12 vs. 2.70 ± 0.44 μg/mg and insoluble Aβ42 0.27 ± 0.02
vs. 0.60 ± 0.11 μg/mg in rApoJ-treated group compared
to the saline-treated group, p < 0.01) (Fig. 3b, c). How-
ever, after treatment with rHDL-rApoJ nanodiscs, the in-
soluble Aβ40 levels remained unaltered, whereas lower
insoluble Aβ42 brain levels were found in comparison
with the saline-treated group (insoluble Aβ42 0.38 ± 0.07
vs. 0.60 ± 0.11 μg/mg in rHDL-treated group compared
to the saline-treated group, p < 0.05) (Fig. 3b, c). Regard-
ing the cerebral Aβ distribution, the number of
Aβ-affected vessels and the number of parenchymal de-
posits were quantified by ThS staining and immunohis-
tochemistry with a specific anti-Aβ antibody (Fig. 3d–f ).
Brains from mice treated with rHDL-rApoJ and free
rApoJ presented a significantly lower number of
CAA-affected arteries as detected by ThS staining (the
Fig. 1 Levels of cerebral insoluble Aβ and mouse ApoJ expression in APP23 transgenic mice over time. a Cerebral accumulation of insoluble Aβ40
in 15- and 24-month-old APP23 and wt mice. b Cerebral accumulation of insoluble Aβ42 in 15- and 24-month-old APP23 and wt mice. c Mouse
ApoJ (m-ApoJ) cerebral expression in 15- and 24-month-old APP23 and wt mice. d Mouse ApoJ (m-ApoJ) levels in the plasma of 15 and 24-month-old
APP23 mice. Data are expressed as the mean ± SEM. N = 3–4/group. *p < 0.05; **p < 0.01; *p < 0.001
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reduction percentages were 64.9% and 54.8% vs.
saline-treated group, respectively) (Fig. 3d). Although no
differences were detected in the parenchymal Aβ depos-
ition load after rApoJ-based treatments (Fig. 3e, f ), the
mean size of fibrillar Aβ accumulations (ThS-positive
deposits) was reduced in those mice treated with free
rApoJ (the reduction percentage in free rApoJ vs.
saline-treated group was 17.5%) (Fig. 3e). Finally, the de-
position load and size of parenchymal Aβ deposits did
not differ significantly among groups as shown by a spe-
cific immunostaining against Aβ, although a clear ten-
dency towards smaller deposits after both rApoJ-based
treatments was again observed (Fig. 3f ).
Neuronal loss is one of the neuropathological hall-
marks in AD [41], and it has been described that the
APP23 mice model shows a neuronal loss in the CA1 re-
gion of the hippocampus and in the poDG from
12 months of age [39]. Thus, we measured the effect of
rHDL-rApoJ and free rApoJ treatments over the neuro-
degeneration in the cortex and hippocampus through
NeuN immunostaining. In comparison with
age-matched wt mice, we found that 15-month-old
APP23 mice exhibited a neuronal reduction in CA1 and
poDG (Fig. 4). Importantly, the treatment with free
rApoJ was able to significantly ameliorate the neuronal
loss in both CA1 and poDG in comparison to the
saline-treated group (Fig. 4).
Because an increase in fibrillary Aβ in the brain is as-
sociated with low levels of particular Aβ species in the
CSF of AD and CAA patients (Aβ42 and Aβ40, respect-
ively [42, 43]), we analyzed the Aβ levels in CSF 30 min
after the last treatment in APP23 mice. We observed a
significant increase in CSF Aβ40 levels in mice treated
with free rApoJ compared to the rest of the groups
(17.10 ± 1.83 vs. 10.46 ± 1.47 ng/ml in the saline-treated
group, p < 0.01) (Fig. 5a). However, Aβ40 levels in plasma
were not different among groups 30 min after the last in-
fusion (Fig. 5b). Circulating levels of Aβ42 in APP23
mice were undetectable in all cases. In addition, we ex-
plored the expression of different brain receptors previ-
ously described to mediate the transport of Aβ across
the BBB [10]. In this context, the expression of LRP-1 or
RAGE did not exhibit expression differences among
groups (Fig. 5c). Moreover, we also eliminated the possi-
bility that the decrease in insoluble Aβ in the brain and
the increase in CSF Aβ levels obtained after peripheral
Fig. 2 Subchronic intravenous treatment of APP23 mice with human recombinant ApoJ (h-rApoJ). a Schematic timeline representing the experimental
design of the study based on the subchronic administration of APP23 mice with rHDL-rApoJ nanodiscs, free rApoJ or saline. b Immunodetection (anti-h-
ApoJ) of treatment samples before being intravenously infused. c Plasmatic levels of h-ApoJ in treated mice 30min after the last administration detected
by ELISA (N= 7/group). d Levels of h-ApoJ in brain homogenates from treated mice detected by ELISA (N= 7/group). e Immunofluorescent detection of
h-ApoJ in paraffin-embedded brain sections. **p< 0.01; ***p< 0.001
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rApoJ treatment could be explained by an alteration of
APP transgene expression or the Aβ peptide production
process. Specifically, we confirmed that the expression
of APP was unaltered in the brains of mice receiving dif-
ferent treatments, and the processing of APP mediated
by α-secretase, β-secretase, and γ-secretase was also un-
changed among groups (Additional file 1: Figure S2).
The neuroinflammatory state of mice that received
ApoJ-based treatments was first analyzed by exploring
the expression levels of specific cellular markers in brain
homogenates. On this front, we determined that the
presence of the activated astrocytic protein GFAP did
not differ after treatments (Fig. 6a). On the other hand,
we detected a 2.3-fold increase in the levels of the lyso-
somal marker CD68 in brain homogenates from free
ApoJ-treated mice (p < 0.05), whereas the expression of
the resident microglial marker Iba-1 was not signifi-
cantly different among groups (Fig. 6b). Iba1 and CD68
localization was determined by immunofluorescence,
and the signal was observed in the periphery of paren-
chymal Aβ-positive deposits, showing elevated CD68 ex-
pression levels in mice treated with free rApoJ (Fig. 6c,
d). Furthermore, double staining of CD68 with tomato
lectin (TL) confirmed the presence of this lysosomal
marker in microglial cells (Fig. 6e). Additionally, a multi-
plexed ELISA was performed to detect the global inflam-
matory state in the brain parenchyma (the complete list
of molecules analyzed can be found in Additional file 1:
Table S1). Despite the phagocytic phenotype shown by
microglial cells after the free rApoJ treatment, we did
Fig. 3 Cerebral Aβ levels in 15-month-old APP23 mice treated subchronically with saline, rHDL-rApoJ nanodiscs, or free rApoJ. a Cerebral soluble
Aβ40 levels. b Cerebral insoluble Aβ40. c Cerebral insoluble Aβ42, detected by ELISA. d Representative images showing ThS-positive vessels and
the corresponding quantification in brain sections. e Representative images showing ThS-positive deposits, quantification of the number of ThS-
positive deposits per area (px2), and quantification of the mean size of those deposits. f Representative images of anti-Aβ (4G8)-positive deposits
in the brain parenchyma, quantification of the number of Aβ-positive deposits per area (px2), and quantification of the mean size of those
deposits. Data are expressed as the mean ± SEM. N = 7/group. *p < 0.05; **p < 0.01
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not observe an increase in the levels of prevalent brain
cytokines and inflammatory molecules, such as the clas-
sical mediator interleukin 1-β (IL-1β) or tumor necrosis
factor-α (TNF-α). In fact, we detected reduced levels of
interleukin 17 (IL17) and KC (keratinocyte chemo-
attractant chemokine) in the brains from mice treated
with both rHDL-rApoJ and free rApoJ. However, after
FDR correction, only levels of IL17 and KC in free
r-ApoJ-treated brains remained statistically different
than the corresponding levels in the saline-treated group
(Table 1).
Finally, the potential direct effect of free rApoJ on micro-
glial phagocytic activity was tested in vitro. BV2 microglial
mouse cells were pretreated with or without rApoJ (0.1 μM)
for 24 h and then incubated with HyLite Fluor 488-labeled
Aβ40 (0.5 μM) for 3 h. Confocal images revealed that
rApoJ-pretreated cells retained higher fluorescent-labeled
Aβ40 levels than non-pretreated cells (Fig. 7a), indicating
higher Aβ uptake in cells challenged with rApoJ. The pres-
ence of fluorescent-labeled Aβ40 inside the cells was corrob-
orated in confocal microscope z-stack images (Fig. 7b). In
addition, quantification of HyLite Fluor 488-labeled Aβ40 in-
ternalized in cultured cells was determined fluorometrically.
Results confirmed that rApoJ-pretreated cells significantly
enhanced the Aβ phagocytic activity compared with
non-pretreated cells (Fig. 7c).
Discussion
Despite the high socioeconomic impact of AD and
CAA, these diseases lack an effective disease-modifying
therapy. The involvement of ApoJ in AD is widely ac-
knowledged, although its underlying mechanism in this
pathology is not yet elucidated. Therefore, the principal
aim of our study was to test the potential protective role
of peripheral ApoJ in an experimental model of AD/
CAA. To this end, we first considered the need to evalu-
ate the effect of the progressive Aβ deposition on cere-
bral endogenous mouse ApoJ levels. In fact, we
confirmed that, in the APP23 mouse model, the accu-
mulation of both insoluble Aβ40 and Aβ42 was accom-
panied by an increase in mouse ApoJ expression in the
brain. This increase in ApoJ has also been described in
AD and CAA patients [44, 45], although it is not clear
whether the increase in brain ApoJ levels promotes or
prevents the Aβ accumulation and toxicity. In this
regard, the elevated circulating levels of ApoJ observed
in AD patients have been proposed to be a protective re-
sponse against the pathologic Aβ deposition [27]. To
confirm this hypothesis, we treated APP23 mice with
rApoJ at the time that mouse ApoJ levels elevation was
not yet significant. This approach allowed us to study
the efficacy of an early increase in peripheral ApoJ in
terms of Aβ deposition, neuronal loss, and
Fig. 4 Neuronal loss in 15-month-old wt mice and APP23 mice treated subchronically with saline, rHDL-rApoJ nanodiscs or free rApoJ. a
Representative images of NeuN-positive cells in CA1 region of the hippocampus and in poDG of APP23-treated mice and wt mice. b
Quantification of NeuN-positive cells per square millimeter in the different studied regions (cortex, CA1, CA2/CA3, and poDG). Abbreviations: Ctx:
Cortex; poDG: polymorphic layers of the dentate gyrus. Data are expressed as the mean ± SEM. N = 6–7/group. *p < 0.05 (comparison between
WT and saline-APP23 groups) and p < 0.05 (comparison among APP23-treated groups)
Retana et al. Alzheimer's Research & Therapy           (2019) 11:42 Page 10 of 17
neuroinflammation. Indeed, the strategy was to increase
the circulating levels of ApoJ in mice following two dif-
ferent treatments: intravenous administration of free
rApoJ or rHDL-rApoJ nanodiscs. Several lines of evi-
dence support the relevance of cholesterol and HDL me-
tabolism to AD [46], and we previously observed the
increased ability of rHDL-rApoJ nanodiscs to promote
the efflux of cholesterol esters in vitro [34]. Therefore,
we believed that the peripheral administration of
rHDL-rApoJ could shed light on the effect of lipidation
on the functionality of ApoJ in cerebral β-amyloidosis.
After 1 month of subchronic administration of treat-
ments based on human rApoJ, we confirmed the pres-
ence of h-rApoJ in plasma. However, we were not able
to detect h-rApoJ in the brains of mice treated with
rHDL-rApoJ or free rApoJ. It has previously been de-
scribed that ApoJ is able to cross the BBB [47]. Based on
this, we expected that the infused rApoJ could enter the
brain parenchyma, but the human protein was detected
by immunofluorescence only on the luminal side of oc-
casional leptomeningeal vessels in both rApoJ-based
treatment groups. In fact, we previously observed spe-
cific vascular accumulation of rHDL-rApoJ nanodiscs in
very old (28 months) APP23 mice [34]. After the corre-
sponding subchronic peripheral treatment in APP23
mice, the cerebral Aβ load was evaluated. Free
rApoJ-treated mice showed significant prevention of
both insoluble Aβ40 and Aβ42 accumulation in compari-
son with the saline-treated group. In turn, the treatment
with rHDL-rApoJ nanodiscs resulted in the prevention
of insoluble Aβ42 accumulation. When we analyzed the
distribution of Aβ, we observed a reduced number of
Aβ-affected vessels in both rApoJ-based treatments. This
reduction was in accordance with a previous published
study [31], where authors described a marked exacerba-
tion of CAA in APP/PS1/Clu−/− mutant mice. The au-
thors proposed that the lack of Clu impaired an efficient
Aβ clearance across the BBB, promoting the accumula-
tion of Aβ in perivascular spaces. However, this same
study showed a clear reduction of parenchymal Aβ accu-
mulation and total Aβ in APP/PS1 mice lacking Clu
[31]. After this, another study showed that 5xFAD/
Clu−/− mice had less Aβ cerebral accumulation only in
young mice, although this effect disappeared with age
[32]. Beyond the valuable information obtained from
these knockout models, we consider that our approach,
based on the peripheral administration of rApoJ, allowed
us to study the role of human ApoJ in contrast to mur-
ine ApoJ and to focus specifically on the effect of a cir-
culating increase in ApoJ levels. As mentioned, our
results obtained in aged APP23 mice treated with rApoJ
partly agreed with the effect observed in the APP/PS1/
Clu−/− mutant mice described by Wojtas et al. [31], since
we detected a significant reduction in the CAA load
after treatments. Thus, it can be speculated that the
localization of human rApoJ in brain vessels after the
peripheral subchronic treatment directly stimulated the
clearance of Aβ from perivascular drainage spaces redu-
cing the Aβ vascular load. However, we also observed
that the peripheral increase of human rApoJ reduced the
Fig. 5 Effect of rHDL-rApoJ nanodiscs or free rApoJ treatment on circulating Aβ levels. a CSF levels of Aβ40 detected by ELISA. b Plasmatic Aβ40 levels
detected by ELISA. c Expression of Aβ-transporting receptors (LRP-1 and RAGE) determined by Western blot. Data are expressed as the
mean ± SEM. N = 5–7 group. *p < 0.05; **p < 0.01
Retana et al. Alzheimer's Research & Therapy           (2019) 11:42 Page 11 of 17
Fig. 6 (See legend on next page.)
Retana et al. Alzheimer's Research & Therapy           (2019) 11:42 Page 12 of 17
total insoluble Aβ in the brain, which was accompanied
by a decrease in the size of the fibrillar Aβ deposits.
Interestingly, these effects were observed without detect-
ing the human rApoJ protein inside the brain. In fact,
intravenous infusion of free ApoJ induced an increase in
Aβ levels in CSF, which might reflect an Aβ mobilization
process from the brain parenchyma. On the other hand,
it has recently been proposed that intraventricular ad-
ministration of an ApoJ mimetic peptide promotes the
amelioration of both parenchymal and vascular Aβ accu-
mulation and improved the cognitive function if the
Tg6799 mouse model [48]. These results can be under-
stood as complementary to ours, as they focused only on
the intracerebral pool of ApoJ. Therefore, to our know-
ledge, our study is the first to administrate human
recombinant ApoJ, produced in mammalian cells, in a
preclinical model of AD. We believe that this is espe-
cially relevant due to the high structural complexity of
ApoJ and the importance of its full-length form for its
functionality [49].
Another beneficial effect of subchronic IV treatment
with free rApoJ in APP23 mice was the prevention of
neuronal loss in CA1 and poDG of the hippocampus.
Due to the association between Aβ deposits and neuro-
degeneration [50], the reduced Aβ levels observed in free
rApoJ-treated mice could explain the amelioration of
neuronal death. Once again, as shown by the effect on
Aβ load after treatments, rHDL-rApoJ was less effective
than the free protein, suggesting that the structural
modification of ApoJ due to its lipidation may alter its
ability to activate some of the protective pathways within
the brain. The inflammatory state of mouse brains after
ApoJ-based treatments was also determined. Treatment
with free rApoJ or rHDL-ApoJ did not induce changes
in the reactivity of astrocytes. Likewise, microglial prolif-
eration was not altered among the treatment groups, but
a significant increase in the expression of brain CD68 in
free rApoJ-treated mice was observed. CD68 was local-
ized surrounding Aβ parenchymal deposits in cells posi-
tive for the TL dye, which stains microglia and other
cells, such as macrophages and endothelial cells [40, 51].
In this context, CD68 is a lysosomal protein that has
been widely used as a marker of phagocytic activity [52].
Accordingly, we demonstrated that rApoJ had a direct
(See figure on previous page.)
Fig. 6 Levels of astrocytic and microglial markers in APP23 mice treated subchronically with saline, rHDL-rApoJ nanodiscs, or free rApoJ. a Expression of
the reactive astrocyte marker GFAP in mouse APP23-brain homogenates after treatments. b Expression of microglial markers (CD68 and Iba-1) in mouse
APP23-brain homogenates after treatments. Data are expressed as the mean ± SEM. N= 6–7/group. *p< 0.05. c Representative immunofluorescence
images showing the localization of Iba1 and d representative immunofluorescence images showing the localization of CD68 around anti-Aβ (4G8)-positive
deposits in brain slices from APP23 mice. e Representative immunofluorescence images showing the localization of CD68 with tomato lectin (TL, as a
microglial marker) in brain slices from APP23 mice
Table 1 Effect of rHDL-rApoJ nanodiscs or free rApoJ on brain inflammatory status, analyzed by multiplexed ELISA. Data are
expressed as the mean ± SEM. N = 5–7/group. *p < 0.05 and **p < 0.01 refer to statistical differences vs. the saline-treated group
determined by one-way ANOVA test (plus multiple comparison test). The false discovery rate (FDR) correction was used to control
for multiple testing in the multiplexed analysis of brain inflammatory status
Inflammatory
markers
APP23 saline
(pg/mg)
APP23 rHDL-
rApoJ (pg/mg)
APP23 free
rApoJ (pg/mg)
One-way ANOVA (3
groups) p value
rHDL-rApoJ vs saline FDR-
corrected p value
Free rApoJ vs saline FDR-
corrected p value
FGF-basic 984.4 ± 154.6 895.6 ± 113.3 560.2 ± 151.4 p = 0.108 p = 0.787 p = 0.174
IL-1β 85.28 ± 12.17 50.86 ± 3.75 72.91 ± 11.43 p = 0.080 p = 0.122 p = 0.448
IL2 151.0 ± 13.09 116.7 ± 14.22 125.2 ± 14.49 p = 0.222 p = 0.198 p = 0.324
IL5 141.7 ± 26.35 130.61 ± 27.54 148.0 ± 21.31 p = 0.893 p = 0.819 p = 0.874
IL6 203.1 ± 22.15 177.7 ± 28.82 176.3 ± 19.5 p = 0.656 p = 0.583 p = 0.448
IL13 21.31 ± 3.40 17.68 ± 2.34 12.63 ± 3.22 p = 0.171 p = 0.552 p = 0.183
IL17 20.01 ± 2.33 13.9 ± 1.37* 10.23 ± 1.08** p = 0.004 p = 0.122 p = 0.017
IFN-γ 127.8 ± 15.53 89.81 ± 13.28 94.08 ± 10.68 p = 0.123 p = 0.137 p = 0.194
IP10 54.4 ± 4.34 44.48 ± 5.11 46.71 ± 5.05 p = 0.330 p = 0.289 p = 0.388
KC 1558 ± 115.5 1206 ± 112.0* 1043 ± 104.6** p = 0.012 p = 0.122 p = 0.029
MIG 81.65 ± 8.21 57.81 ± 6.91 61.48 ± 8.72 p = 0.090 p = 0.122 p = 0.194
TNF-α 127.2 ± 13.46 125.2 ± 9.43 144.7 ± 17.79 p = 0.620 p = 0.937 p = 0.448
VEGF 17.67 ± 2.36 14.27 ± 2.35 10.72 ± 1.22 p = 0.080 p = 0.399 p = 0.129
MCP-1 36.1 ± 3.93 24.31 ± 2.84 28.19 ± 3.12 p = 0.060 p = 0.122 p = 0.194
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role enhancing the Aβ uptake by microglial cells in vitro,
as previously proposed [53]. However, infiltrated mono-
cytes have previously demonstrated a higher ability than
microglial cells to phagocytose Aβ peptide [14, 54]. Be-
cause resident microglia and peripheral macrophages
consist of heterogeneous populations that in many ways
are indistinguishable entities [55], the detailed mecha-
nisms implicated in the stimulation of phagocytosis in
brain myeloid cells by peripheral ApoJ merit exploration
in future studies.
As mentioned, it has been extensively demonstrated
that brain myeloid cells participate in Aβ elimination
through phagocytosis and that stimulation of the im-
mune response in the CNS ameliorates Aβ deposition
[56, 57]. Therefore, promoting the phagocytic ability of
these cell types could be a potential strategy to prevent
cerebral Aβ deposition. Nevertheless, the exact role of
myeloid cells in pathological conditions is under discus-
sion, since it has been observed that, for example, cul-
tured microglia produce high levels of neurotoxic
cytokines in response to Aβ stimulation [58]. To test
whether the enhancement of phagocytic pathways was
accompanied by an increased release of inflammatory
molecules, we analyzed the overall inflammatory state of
brains after treatments. We did not observe an increase in
the cerebral levels of classical proinflammatory molecules
after treatments. In fact, reduced neuroinflammation was
observed in the brains of rApoJ-treated mice in comparison
with saline-treated APP23 mice, as shown by the significant
reductions in IL17 and KC (the mouse homolog of CXCL1)
levels, especially in free rApoJ-treated mouse brains. In this
context, higher expression of IL17 has been linked to BBB
disruption and neurotoxicity [59, 60], and KC chemokine
levels in the brain have been associated with memory
Fig. 7 Effect of rApoJ treatment on Aβ phagocytic activity of microglial cultured cells. a Representative micrographs corresponding to BV2 cells
pre-incubated during 24 h with/without rApoJ (0.1 μM) and then treated for 3 h with HiLyte Fluo 488-Aβ40 (0.5 μM). Blue arrows indicate cells
containing HiLyte Fluo 488-Aβ40 (green). Cell morphology, visualized by TRITC-phalloidin staining, and cell nuclei with Dapi are shown in gray.
b Confocal image showing the z-stack of a single cell containing HiLyte Fluo 488-Aβ40 (green), stained with TRITC-phalloidin (red), and Dapi
(blue). c Fluorometric quantification of HiLyte Fluo 488-Aβ40 in fixed BV2 cells (Ex/Em = 503/528 nm). Data is expressed as mean ± SEM of 4
independent experiments performed in duplicates. *p < 0.05; ***p < 0.001
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deficits [61]. This last result agrees with previous studies
that demonstrated anti-inflammatory and anti-apoptotic
properties of ApoJ/Clu [62].
In summary, beyond the accepted implication of ApoJ
in cerebral β-amyloidosis, our study is the first to dem-
onstrate that the intravenous administration of human
recombinant ApoJ is safe and effective reducing the
levels of cerebral insoluble Aβ and the CAA load. In-
deed, our results confirm that peripheral interventions
offer low invasive opportunities to regulate the cerebral
β-amyloid load. An important limitation of our study is
the lack of functional analysis after treatments, even
though we have demonstrated that free rApoJ treatment
prevents neuronal loss in the hippocampus in old
APP23 mice. Further studies testing the efficacy of rApoJ
treatment using different models of AD will be relevant
to analyze its impact on behavior and cognition. We
suggest that peripheral rApoJ promotes the amelioration
of cerebral β-amyloidosis acting at the vascular level and
upregulating specific phagocytic pathways in myeloid
cells. However, the exact molecular pathway activated by
peripheral ApoJ mediating the stimulation of the phago-
cytic phenotype needs to be elucidated in future studies.
Additional file
Additional file 1: Figure S1. Effect of rHDL-rApoJ or free rApoJ treat-
ment in the levels of mouse ApoJ in brain homogenates and plasma
from treated mice, determined by ELISA. Data are expressed as the mean
± SEM. N = 3–4/group. Figure S2. Effect of rHDL-rApoJ or free rApoJ
treatment in the expression of full-length APP protein and the processing
of APP through α-, β-, and γ secretases. a) Representative Western blots
showing the relative amount of full-length APP, sAPPα, sAPPβ, and CTF-
APP. Relative quantification of b) full-length APP, c) sAPPα, d) sAPPβ, and
e) CTF-APP levels after treatments. Data are expressed as the mean ±
SEM. N = 6/group. Table S1. List of abbreviation of tested inflammatory
molecules by multiplexed ELISA. (DOCX 302 kb)
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